检索结果-南通市图书馆

Efficacy and safety of chimeric antigen receptor-t cells in the treatment of B cell lymphoma:a systematic review and meta-analysis

引用

Chinese Medical Journal 2020年第1期133卷 74-85页

作者： Xiao-Hong Zheng Xi-You Zhang Qian-Qian Dong Feng Chen Shou-Bo Yang Wen-Bin Li Departm ent of Neuro-Oncology Neurosurgery CenterBeijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of Nephrology Beijing Shijitan HospitalCapital Medical UniversityBeijing 100038China Department of General Medicine Ningbo Medical CenterLi Huili HospitalNingboZhejiang 315000China

Background:Conventional treatment has limited efficacy in relapsed/refractory B-cell *** chimeric antigen receptor t-cell(CAR-t)technology has shown high safety and results in high remission rates,we investigated its efficacy and safety in B-cell lymphoma treatment and analyzed potential affecting factors to provide evidence for therapeutic strategies and ***:We searched databases including PubMed,Embase,and Cochrane up to July ***-analysis 1 was conducted to study the efficacy of CAR-t cell for treating B-cell lymphoma,measuring the response rate and complete remission rate as ***-group analysis was performed for age,pathological type,target antigen,co-stimulatory molecule,and conditioning ***-analysis 2 was undertaken on the safety of the treatment with the incidence rate of toxicity(cytokine-releasing syndrome[CRS],neurotoxicity)as an ***:Seventeen studies were included in the systematic review and *** was found that CAR-t cells had good therapeutic effects in the following cases:B-cell lymphoma(patients≥65 years old);diffuse large B-cell lymphoma pathological type;patients with treatment target antigen other than CD19;patients treated with co-stimulatory molecules other than CD28,including 4-1BB+CD28 or 4-1BB;and patients treated with cyclophosphamide/fludarabine pre-treatment protocol conditioning *** the CRS and neurotoxicity incidences were high,most were reversible with minimal risk of ***:CAR-t cell treatment is safe for clinical application;however,toxicity effects should be monitored.

关键词： Lymphoma B-cell Meta-analysis chimeric antigen receptor t-cell

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR t-cells via tGF-βsignaling

引用

Frontiers of Medicine 2024年第1期18卷 128-146页

作者： Yuanyuan Hao Panpan Chen Shanshan Guo Mengyuan Li Xueli Jin Minghuan Zhang Wenhai Deng Ping Li Wen Lei Aibin Liang Wenbin Qian Department of Hematology The Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhou310009China Department of Hematology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China Key Laboratory of Laboratory Medicine Ministry of EducationSchool of Laboratory Medicine and Life SciencesWenzhou Medical UniversityWenzhou325000China Department of Hematology Tongji Hospital of Tongji UniversityShanghai200065China

tumor-derived exosomes (tEXs) enriched in immune suppressive molecules predominantly drive t-cell dysfunction and impair antitumor immunity. chimeric antigen receptor (CAR) t-cell therapy has emerged as a promising treatment for refractory and relapsed hematological malignancies, but whether lymphoma tEXs have the same impact on CAR t-cell remains unclear. Here, we demonstrated that B-cell lymphoma-derived exosomes induce the initial activation of CD19-CAR t-cells upon stimulation with exosomal CD19. However, lymphoma tEXs might subsequently induce CAR t-cell apoptosis and impair the tumor cytotoxicity of the cells because of the upregulated expression of the inhibitory receptors PD-1, tIM3, and LAG3 upon prolonged exposure. Similar results were observed in the CAR t-cells exposed to plasma exosomes from patients with lymphoma. More importantly, single-cell RNA sequencing revealed that CAR t-cells typically showed differentiated phenotypes and regulatory t-cell (treg) phenotype conversion. By blocking transforming growth factor β (tGF-β)-Smad3 signaling with tGF-β inhibitor LY2109761, the negative effects of tEXs on treg conversion, terminal differentiation, and immune checkpoint expression were rescued. Collectively, although tEXs lead to the initial activation of CAR t-cells, the effect of tEXs suppressed CAR t-cells, which can be rescued by LY2109761. A treatment regimen combining CAR t-cell therapy and tGF-β inhibitors might be a novel therapeutic strategy for refractory and relapsed B-cell lymphoma.

关键词： tumor-derived exosome chimeric antigen receptor t-cell lymphoma tGF-β

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

EBV-associated lymphoproliferative disease post-CAR-t cell therapy

引用

Frontiers of Medicine 2024年第2期18卷 394-398页

作者： Shiyuan Zhang Xiaoxi Zhou Shangkun Zhang Na Wang tongcun Zhang Donghua Zhang Qilin Ao Yang Cao Liang Huang Department of Hematology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan430030China Immunotherapy Research Center for Hematologic Diseases of Hubei Province Wuhan430030China Institute of Biology and Medicine College of Life and Health SciencesWuhan University of Science and TechnologyWuhan430081China Department of Pathology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan430030China State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood DiseasesHaihe Laboratory of Cell EcosystemInstitute of Hematology&Blood Diseases HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjin300020China tianjin Institutes of Health Science Tianjin301600China

Epstein–Barr virus(EBV)-associated lymphoproliferative diseases(EBV-LPDs)are common complications that occur after solid organ transplantation or allogeneic hematopoietic stem-cell transplantation(HSCt).However,their occurrence and treatment post-chimeric antigen receptor-modified t(CAR-t)cell therapy has not been *** patients had been diagnosed with EBV-positive aggressive B-cell lymphoma and experienced relapses after multiple lines of *** receiving CAR-t cell therapy in tandem with autologous HSCt,the patients achieved complete ***,with a median time of 38.5 months after CAR-t cell therapy,B-cell-derived EBV-LPDs were diagnosed,and they were relieved through the administration of immune checkpoint inhibitor or B-cell-depleting ***,our report suggests that EBV-LPDs may represent a long-term adverse event after CAR-t cell therapy,especially in patients who previously had EBV-positive disorders,and they can be resolved by immune normalization strategy or B-cell depleting therapy.

关键词： EBV-associated lymphoproliferative disease chimeric antigen receptor t-cell autologous stem cell transplantation immune checkpoint inhibitor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chimeric antigen receptor modified t-cells for cancer treatment

引用

慢性疾病与转化医学(英文) 2018年第4期4卷 225-243页

作者： Han Xiao Wang Yao Han Wei-Dong Molecular & Immunological Department Bio-therapeutic Department The General Hospital of People''s Liberation Army Beijing China

t cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. the anti-cluster of differentiation (CD)19 CAR-t cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR-t cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR-t in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR-t cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR-t and some novel CAR designs, the clinical application of CAR-t cell therapies, as well as the assessment and management of toxicities.

关键词： chimeric antigen receptor t-cell Hematologic malignancies Solid tumor toxicities

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：